AstraZeneca has agreed to pay $875 million up front--and up to $2.2 billion total, with milestones--for Almirall's respiratory portfolio. The deal brings a couple of marketed drugs, and a list of pipeline meds that includes a combo drug Almirall is developing with U.S.-based Forest Laboratories.
No news isn't good or bad for Pfizer deal-watchers. It's just no news. Anyone hoping for a halfway-clear idea of CEO Ian Read's next buyout move was disappointed after Tuesday's second-quarter earnings call with analysts.
Looks like Pfizer's finally getting the vaccines expansion it's been hankering for. The company agreed to pick up Baxter's marketed vaccines portfolio for $635 million, building up its own business as the Illinois healthcare company slims down for a pharma unit spinoff next year.
AstraZeneca has signed an agreement to pick up Almirall's respiratory business for up to $2.1 billion, hoping to shoulder its way to the front of a blockbuster market for COPD treatments.
Nobel Biocare has confirmed it is in early discussions with potential buyers, after a Bloomberg article reported a rumored sale. The report said the company has hired Goldman Sachs to broker a transaction.
Let GlaxoSmithKline be clear: It's open to spinning off its consumer healthcare division at some nebulous point in the future. But it's not happening anytime soon.
With the acquisition of surgical technology company Visualase, Medtronic is further bolstering one of its own fastest growing segments--as well as a large and fast growing group for Covidien. Medtronic expects to complete its $42.9 billion acquisition of Covidien by early 2015.
The string of pharma M&A deals fueled by the lure of cutting taxes continues and Midwest-based Hospira is now said to be about to take the plunge. Its vehicle of choice is the medical nutrition business of France's Danone, which sources say it is negotiating to buy in a deal that could run to $5 billion.
The Medtronic merger with Covidien could offer a particular threat to C.R. Bard's vascular business--its largest segment and one of its fastest growing. The company was clear that it's actively in the market for its own strategic acquisitions; it hasn't disclosed a sizeable deal in almost a year.
It remains to be seen whether unconventional M&A tactics from Valeant's takeover partner, Bill Ackman, will help the pair get a deal for Allergan done. But in the meanwhile, one lawmaker is putting heat on the SEC to consider revising the rules that allowed them.